LAS VEGAS, Nev. (KRNV & MyNews4.com) - Nevada and 37 other states have reached a $90 million consent judgment with GlaxoSmithKline LLC over GlaxoSmithKline promotion of its diabetes drug, Avandia.
Attorneys Generals from the states allege that GlaxoSmithKline engaged in unfair and deceptive practices by misrepresenting Avandia’s cardiovascular risks and safety profile. Nevada's Attorney General said, "These enforcement provisions are important to protect Nevadans and others across the country... I am pleased to join this multistate agreement to ensure that Nevadans are not misled by this company’s deceptive marketing practices."
GlaxoSmithKline agreed to reform how it markets and promotes diabetes drugs.
The Nevada Attorney General's Office tells News 4 the state will receive $1,521,178 as its share of the settlement, but did not immediately say where that money would be sent.
The investigation was led by the Attorneys General of Oregon and Illinois with an Executive Committee consisting of the Attorneys General of Arizona, Florida, Maryland, Pennsylvania, Tennessee, and Texas. Also participating in the settlement are Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Hawaii, Idaho, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Rhode Island, South Dakota, Vermont, Washington, and Wisconsin.